Workflow
Novum LVP
icon
Search documents
BAX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Prnewswire· 2025-10-20 01:03
Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with these defects but failed to adequately address the issues through customer alerts [3]. - The company's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price dropped by 22.4%, closing at $21.76 [4]. - Investors who suffered losses between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].
BAX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Globenewswire· 2025-10-19 16:00
Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for alleged violations of federal securities laws related to the Novum LVP device malfunctions, which posed serious risks to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Baxter securities between February 23, 2023, and July 30, 2025 [2]. - Allegations include that Baxter misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Baxter have until December 15, 2025, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
Globenewswire· 2025-10-19 00:17
Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, due to alleged misleading information regarding the safety and efficacy of the Novum LVP product line [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which led to malfunctions that posed serious risks to patients, including underinfusion, overinfusion, and non-delivery of fluids [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [5]. - The lawsuit alleges that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Class Action Participation - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
Prnewswire· 2025-10-17 23:48
Accessibility StatementSkip Navigation NEW YORK, Oct. 17, 2025 /PRNewswire/ -- What to do next: To join the Baxter class action, go to https://rosenlegal.com/submit-form/?case_id=17664 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of oth ...
Stockholder Alert: Robbins LLP Informs Baxter International, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company
Prnewswire· 2025-10-17 21:34
Accessibility StatementSkip Navigation SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025. Baxter is a global company that develops, manufactures, and markets medical products used in hospitals and other healthcare facilities. For more information, submit a form, email attorney Aaron Dumas, Jr., ...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Baxter International, Inc. (BAX)
Globenewswire· 2025-10-17 15:39
Core Viewpoint - A securities class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered from systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of all individuals or entities that purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter failed to disclose significant issues with the Novum LVP, including systemic defects that caused malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [2]. Group 2: Implications for Baxter - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter might have to halt all new sales of these pumps [2]. - The statements made by Baxter regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Group 3: Investor Actions - Investors who acquired shares of Baxter are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 15, 2025 [3].